The comparatively good prognosis of cancers with small 6q15 deletions observed in our study is also in line with our observation in the initial functional screen that an unequivocal tumor suppressive role could not be seen for any of the five genes (MDN1, CASP8AP2, GJA10, BACH2, MAP3K7) that had earlier been located to the deletion epicenter at 6q15 in prostate cancer before [6, 23-26]. This evidence concerns the gene BACH2 and Familial prostate cancer.